Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway - PaVDaG study)

BMJ Open

Volumn 6, Issue 4, 2016, Pages

  Stanczuk, Grazyna ^a,b   Baxter, Gwendoline ^a   Currie, Heather ^a   Lawrence, James ^a   Cuschieri, Kate ^c   Wilson, Allan ^d   Arbyn, Marc ^e  

^a DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d MONKLANDS HOSPITAL   (United Kingdom)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER IMMUNIZATION; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEASIBILITY STUDY; FEMALE; GOLD STANDARD; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREVALENCE; PRIMARY MEDICAL CARE; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; URINALYSIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VAGINA SMEAR; VALIDATION STUDY; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; SCOTLAND; SPECIMEN HANDLING; UTERINE CERVIX; VAGINA; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SCOTLAND; SPECIMEN HANDLING; URINALYSIS; VAGINA;

EID: 84969674507     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010660     Document Type: Article

References (26)

1. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine 2012;30: F88-99.
2. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. International HPV screening working group. Lancet 2014;383:524-32.
3. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-20.
4. Arbyn M, Snijders PJ, Meijer CJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect 2015;211:817-26.
5. Verdoodt F, Jentschke M, Hillemanns P, et al. Reaching women who do not participate in the regular cervical cancer screening program by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur J Cancer 2015;51:2375-85.
6. Gok M, Heideman DAM, van Kemenade FJ, et al. HPV testing on self-collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010;340:c1040.
7. Arbyn M, Castle PE. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical screening programme. Cancer Epidemiol Biomarkers Prev 2015;24:769-72.
8. Snijders PJ, Verhoef VM, Arbyn M, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical screening. Int J Cancer 2013;132:2223-36.
9. Smith LW, Khurshed F, Van Niekerk DJ, et al. Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical screening program. BMC Public Health 2014;14:1060.
10. Arbyn M, Ronco G, Cuzick J, et al. How to evaluate emerging technologies in cervical screening? Int J Cancer 2009;125:2489-96.
11. Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected sample: a meta-analysis. Lancet Oncol 2014;15:172-83.
12. Belinson JL, Du H, Yang B, et al. Improved sensitivity of vaginal self collection and high-risk papillomavirus testing. Int J Cancer 2012;130:1855-60.
13. Sellors JW, Lorincz AT, Mahony JB, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ 2000;163:513-18.
14. Payan C, Tran A, Foll Y, et al. Evaluation of a new strategy for cervical cancer screening in women who do not access to pap smear screening in West Brittany, using a urine test for human papillomavirus (HPV) detection on a large scale platform combining EasyMag extractor and real-time PCR LightCycler system (the PAPU29 Phase 1 study). J Clin Virol 2009;46(Suppl 1):S12.
15. Vorsters A, Micalessi I, Kilcke J, et al. Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol Infect Dis 2011;31:627-40.
16. Pathak N, Dodds J, Zamora J, et al. Accuracy of urine human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ 2014;349:g5264.
17. Stanczuk GA, Currie H, Baxter G, et al. Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment. J Clin Pathol 2015;68:567-70.
18. Meijer CJH, Berkhof DA, Heideman AT, et al. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009;46(3): S1-4.
19. Smith JHF, Patnick J. eds. Achievable standards, benchmarks for reporting and criteria for conducting cervical cytopathology. 2nd edn. Sheffield: NHS Cancers Screening Programmes, 2013. http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp01.html
20. Tang NS, Tang ML, Chan IS. On tests of equivalence via non unity relative risk for matched pair design. Stat Med 2003;22:1217-33.
21. Cuschieri K, Geraets DT, Moore C, et al. Clinical and analytical performance of the Onclarity HPV assay using the VALGENT framework. J Clin Microbiol 2015;53:3272-9.
22. Chock C, Irwing L, Berry G, et al. Comparing dichotomous screening tests when individuals negative on both tests are not verified. J Clin Epidemiol 1997;51:1211-17.
23. Schatzkin A, Connor RJ, Taylor PR, et al. Comparing new and old screening tests when reference procedure cannot be performed on all screenees. Example of automated cytometry for early detection of cervical cancer. Am J Epidemiol 1987;125:672-8.
24. Stoler MH, Wright TC Jr, Sharma A, et al. The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study. Am J Natl Clin Pathol 2012;137:295-303.
25. Won K-H, Lee JY, Cho H-Y, et al. Impact of age on the false negative rate of human papillomavirus DNA test in patients with atypical squamous cells of undetermined significance. Obstet Gynecol Sci 2015;58:117-23.
26. Rositch AF, Silver MI, Burke A, et al. The correlation between HPV positivity and abnormal cervical cytology differs by age among peri-menopausal women. J Low Genital Tract Dis 2013;17:38-47.